

Division of Environmental Hazards and Health Effects, National Center for Environmental Health, Centers for Disease Control and Prevention (CDC), 4770 Buford Highway, Mailstop F-35, Atlanta, GA 30341, telephone (770) 488-7630.

Please refer to Announcement 709 when requesting information and submitting an application.

A copy of "Healthy People 2000" (Full Report; Stock No. 017-001-00474-0) or "Healthy People 2000" (Summary Report; Stock No. 017-001-00473-1) referenced in the "Introduction" may be obtained through the Superintendent of Documents, Government Printing Office, Washington, DC 20402-9325, telephone (202) 512-1800.

Dated: November 6, 1996.

Joseph R. Carter,

Acting Associate Director for Management and Operations, Centers for Disease Control and Prevention (CDC).

[FR Doc. 96-29141 Filed 11-13-96; 8:45 am]

BILLING CODE 4163-18-P

Hospital Infection Control Practices Advisory Committee: Meeting

In accordance with section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92-463), the Centers for Disease Control and Prevention (CDC) announces the following meeting.

Name: Hospital Infection Control Practices Advisory Committee (HICPAC).

Times and Dates: 8:30 a.m.-4:30 p.m., December 12, 1996. 8:30 a.m.-1:30 p.m., December 13, 1996.

Place: CDC, Auditorium A, 1600 Clifton Road, NE, Atlanta, Georgia 30333.

Status: Open to the public, limited only by the space available.

Purpose: The Committee is charged with providing advice and guidance to the Secretary, the Assistant Secretary for Health, the Director, CDC, and the Director, National Center for Infectious Diseases (NCID), regarding the practice of hospital infection control and strategies for surveillance, prevention, and control of nosocomial infections in U.S. hospitals and updating of guidelines and other policy statements regarding prevention of nosocomial infections.

Matters to be Discussed: Agenda items will include a review of the third draft of the Guideline for Infection Control in Hospital Personnel, the Hospital Infections Program organizational structure and activities, proposed plans and outline for revision of the Guideline for Prevention of Surgical Wound Infections, and an update on CDC activities of interest to the Committee.

Agenda items are subject to change as priorities dictate.

Contact Person for More Information: Julia S. Garner, Nurse Consultant, Hospital Infections Program, NCID, CDC, 1600 Clifton Road, NE, M/S A-07, Atlanta, Georgia 30333, telephone 404/639-6408.

Dated: November 7, 1996.

Carolyn J. Russell,

Director, Management Analysis and Services Office, Centers for Disease Control and Prevention (CDC).

[FR Doc. 96-29139 Filed 11-13-96; 8:45 am]

BILLING CODE 4163-18-P

Food and Drug Administration

Advisory Committees; Renewals

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) announces the renewal of certain FDA advisory committees by the Commissioner of Food and Drugs (the Commissioner). The Commissioner has determined that it is in the public interest to renew the charters of the committees listed below for an additional 2 years beyond charter expiration date. The new charters will be in effect until the dates of expiration listed below. This notice is issued under the Federal Advisory Committee Act of October 6, 1972 (Pub. L. 92-463 (5 U.S.C. app. 2)).

DATES: Authority for these committees will expire on the dates indicated below unless the Commissioner formally determines that renewal is in the public interest.

Name of committee	Date of expiration
Pulmonary-Allergy Drugs Advisory Committee	May 30, 1998.
Drug Abuse Advisory Committee	May 31, 1998.
Science Advisory Board to the National Center for Toxicological Research	June 2, 1998.
Peripheral and Central Nervous System Drugs Advisory Committee	June 4, 1998.
Psychopharmacologic Drugs Advisory Committee	June 4, 1998.
Science Board to the Food and Drug Administration	June 26, 1998.
Transmissible Spongiform Encephalopathies Advisory Committee (formerly Ad Hoc Advisory Committee on Creutzfeldt-Jakob Disease)	June 9, 1998.
Allergenic Products Advisory Committee	July 9, 1998.
Cardiovascular and Renal Drugs Advisory Committee	August 27, 1998.
Endocrinologic and Metabolic Drugs Advisory Committee	August 27, 1998.
Oncologic Drugs Advisory Committee	September 1, 1998.
Anti-Infective Drugs Advisory Committee	October 7, 1998.
Dermatologic and Ophthalmic Drugs Advisory Committee	October 7, 1998.
Biological Response Modifiers Advisory Committee	October 28, 1998.

FOR FURTHER INFORMATION CONTACT:

Donna M. Combs, Committee Management Office (HFA-306), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301-827-4820.

Dated: November 6, 1996.

Michael A. Friedman,

Deputy Commissioner for Operations.

[FR Doc. 96-29147 Filed 11-13-96; 8:45 am]

BILLING CODE 4160-01-F

[Docket No. 96F-0415]

Nalco/Exxon Energy Chemicals, L. P.; Filing of Food Additive Petition

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing

that Nalco/Exxon Energy Chemicals, L. P. has filed a petition proposing that the food additive regulations be amended to provide for the safe use of poly(alkyl methacrylate) as a processing aid in the production of petroleum wax.

DATES: Written comments on the petitioner's environmental assessment by December 16, 1996.

ADDRESSES: Submit written comments to the Dockets Management Branch (HFA-305), Food and Drug Administration, 12420 Parklawn Dr., rm 1-23, Rockville, MD 20857.

FOR FURTHER INFORMATION CONTACT: Aydin Örtan, Center for Food Safety and Applied Nutrition (HFS-217), Food and Drug Administration, 200 C St. SW., Washington, DC 20204, 202-418-3076.

SUPPLEMENTARY INFORMATION: Under the Federal Food, Drug, and Cosmetic Act (sec. 409(b)(5) (21 U.S.C. 348(b)(5))), notice is given that a food additive petition (FAP 7A4524) has been filed by Nalco/Exxon Energy Chemicals, L. P., c/o Keller and Heckman, 1001 G St. NW., suite 500 West, Washington, DC 20001. The petition proposes to amend the food additive regulations in § 172.886 *Petroleum wax* (21 CFR 172.886) to provide for the safe use of poly(alkyl methacrylate) as a processing aid in the production of petroleum wax.

The potential environmental impact of this action is being reviewed. To encourage public participation consistent with regulations promulgated under the National Environmental Policy Act (40 CFR 1501.4(b)), the agency is placing the environmental assessment submitted with the petition that is the subject of this notice on public display at the Dockets Management Branch (address above) for public review and comment. Interested persons may, on or before December 16, 1996, submit to the Dockets Management Branch (address above) written comments. Two copies of any comments are to be submitted, except that individuals may submit one copy. Comments are to be identified with the docket number found in brackets in the heading of this document. Received comments may be seen in the office above between 9 a.m. and 4 p.m., Monday through Friday. FDA will also place on public display any amendments to, or comments on, the petitioner's environmental assessment without further announcement in the Federal Register. If, based on its review, the agency finds that an environmental impact statement is not required and this petition results in a regulation, the notice of availability of the agency's finding of no significant impact and the evidence supporting that finding will be

published with the regulation in the Federal Register in accordance with 21 CFR 25.40(c).

Dated: October 23, 1996.

Alan M. Rulis,

*Director, Office of Premarket Approval,
Center for Food Safety and Applied Nutrition.*

[FR Doc. 96-29146 Filed 11-13-96; 8:45 am]

BILLING CODE 4160-01-F

National Institutes of Health

National Institute of Arthritis and Musculoskeletal and Skin Disease; Notice of Closed Meeting

Pursuant to Section 10(d) of the Federal Advisory Committee Act, as amended (5 United States Code Appendix 2), notice is hereby given of the following National Institute of Arthritis and Musculoskeletal and Skin Diseases Special Emphasis Panel (SEP) meeting:

Purpose/Agenda: To review and evaluate research grant applications.

Name of SEP: P60 MAMDC Application Review.

Date of Meeting: November 13-14, 1996.

Time: November 13—8:30 a.m.—5:00 p.m.; November 14—8:30 a.m.—adjournment.

Place of Meeting: Holiday Inn—Bethesda, 8120 Wisconsin Avenue, Bethesda, Maryland 20814.

Scientific Review Administrator: Melvin H. Gottlieb, Ph.D., Natcher Building, 45 Center Drive, Rm. 5AS-25U, Bethesda, Maryland 20892-6500, Telephone: 301-594-4952.

The meeting will be closed in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 United States Code. Applications and/or proposals and the discussions could reveal confidential trade secrets or commercial property such as patentable material and personal information concerning individuals associated with the applications and/or proposals, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

This notice is being published less than 15 days prior to the meeting due to the urgent need to meet timing limitations imposed by the review and funding cycle.

(Catalog of Federal Domestic Assistance Programs Nos. [93.846, Project Grants in Arthritis, Musculoskeletal and Skin Diseases Research], National Institutes of Health, HHS)

Paula N. Hayes,

Acting Committee Management Officer, NIH.

[FR Doc. 96-29338 Filed 11-12-96; 12:57 pm]

BILLING CODE 4140-01-M

National Institute of Mental Health; Notice of Closed Meetings

Pursuant to Section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice

is hereby given of the following meetings of the National Institute of Mental Health Special Emphasis Panel:

Agenda/Purpose: To review and evaluate grant applications.

Committee Name: National Institute of Mental Health Special Emphasis Panel.

Date: November 14—November 15, 1996.

Time: 8:30 a.m.

Place: Double Tree Hotel, 1750 Rockville Pike, Rockville, MD 20852.

Contact Person: Lawrence E. Chaitkin, Parklawn Building, Room 9C-26, 5600 Fishers Lane, Rockville, MD 20857, Telephone: 301, 443-4843.

Committee Name: National Institute of Mental Health Special Emphasis Panel.

Date: November 26, 1996.

Time: 12 p.m.

Place: Parklawn Building, Room 9C-26, 5600 Fishers Lane, Rockville, MD 20857.

Contact Person: Sheri L. Schwartzback, Parklawn Building, Room 9C-26, 5600 Fishers Lane, Rockville, MD 20857, Telephone: 301, 443-4843.

The meetings will be closed in accordance with the provision set forth in secs. 552b(c)(4) and 552b(c)(6), Title 5, U.S.C. Applications and/or proposals and the discussions could reveal confidential trade secrets or commercial property such as patentable material and personal information concerning individuals associated with the applications and/or proposals, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

This notice is being published less than fifteen days prior to the meetings due to the urgent need to meet timing limitations imposed by the review and funding cycle.

(Catalog of Federal Domestic Assistant Program Numbers 93.242, 93.281, 93.282)

Paula N. Hayes,

Acting Committee Management Officer, NIH.

[FR Doc. 96-29339 Filed 11-12-96; 12:57 pm]

BILLING CODE 4140-01-M

DEPARTMENT OF HOUSING AND URBAN DEVELOPMENT

[Docket No. FR-4151-C-02]

Announcement Designations for Campus of Learners for Public and Indian Housing Fiscal Year 1996; Correction

AGENCY: Office of the Assistant Secretary for Public and Indian Housing, HUD.

ACTION: Notice; correction.

SUMMARY: This document contains corrections to a notice which was published on Thursday, October 10, 1996 (61 FR 53232). The notice announced the designation of Campus of Learners for Public and Indian Housing for Fiscal Year 1996.